Novartis AG‘s search for interesting early-stage assets is not confined to the usual US and European markets and the Swiss major’s collaboration with South Korea’s Chong Kun Dang Pharmaceutical Corp. inked earlier this week is a great example, according to Susanne Kreutz, head of corporate and business development.
Novartis Casts Nets Globally To Snap Up Best Assets
The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.
